120 related articles for article (PubMed ID: 8495279)
1. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
Aicardi G; Benso L; Vignolo M; Terragna A; Verrina E; Cordone G; Coppo R; Sernia O; Sardella ML; Di Battista E
Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
[TBL] [Abstract][Full Text] [Related]
2. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
Aicardi G; Milani S; Imbimbo B; Vignolo M; Di Battista E; Gusmano R; Terragna A; Cordone G; Cottafava F; Coppo R
Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
[TBL] [Abstract][Full Text] [Related]
3. Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (deflazacort) versus prednisone. An interim study.
Vignolo M; Milani S; Imbimbo B; Naselli A; Di Battista E; Piaggio G; Leveratto L; Morreale G; Sardella ML; Corsini M
Clin Exp Rheumatol; 1991; 9 Suppl 6():41-5. PubMed ID: 2060177
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
Olgaard K; Storm T; van Wowern N; Daugaard H; Egfjord M; Lewin E; Brandi L
Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
[TBL] [Abstract][Full Text] [Related]
5. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
Rizzato G; Riboldi A; Imbimbo B; Torresin A; Milani S
Respir Med; 1997 Sep; 91(8):449-60. PubMed ID: 9338047
[TBL] [Abstract][Full Text] [Related]
6. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
Broyer M; Terzi F; Lehnert A; Gagnadoux MF; Guest G; Niaudet P
Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.
Balsan S; Stéru D; Bourdeau A; Grimberg R; Lenoir G
Calcif Tissue Int; 1987 Jun; 40(6):303-9. PubMed ID: 3111667
[TBL] [Abstract][Full Text] [Related]
8. Deflazacort induced stronger immunosuppression than expected.
Gonzalez-Castañeda RE; Castellanos-Alvarado EA; Flores-Marquez MR; Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
[TBL] [Abstract][Full Text] [Related]
9. Experience with deflazacort in children and adolescents after renal transplantation.
Schärer K; Feneberg R; Klaus G; Paschen C; Wüster C; Mehls O; Schaefer F
Pediatr Nephrol; 2000 Jun; 14(6):457-63. PubMed ID: 10872183
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
11. Potency ratio--a brief synopsis.
Avioli LV
Br J Rheumatol; 1993 May; 32 Suppl 2():24-6. PubMed ID: 8495276
[TBL] [Abstract][Full Text] [Related]
12. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
[TBL] [Abstract][Full Text] [Related]
14. Deflazacort in juvenile chronic arthritis.
Loftus JK; Reeve J; Hesp R; David J; Ansell BM; Woo PM
J Rheumatol Suppl; 1993 Apr; 37():40-2. PubMed ID: 8501751
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
Scudeletti M; Puppo F; Lanza L; Mantovani L; Bosco O; Iudice A; Imbimbo B; Indiveri F
Eur J Clin Pharmacol; 1993; 45 Suppl 1():S29-34. PubMed ID: 8313931
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of glucocorticoids on calcium absorption and bone mass.
Gennari C
Br J Rheumatol; 1993 May; 32 Suppl 2():11-4. PubMed ID: 8495275
[TBL] [Abstract][Full Text] [Related]
17. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
[TBL] [Abstract][Full Text] [Related]
19. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.
Ganapati A; Ravindran R; David T; Yadav B; Jeyaseelan V; Jeyaseelan L; Danda D
Lupus; 2018 May; 27(6):890-898. PubMed ID: 29320974
[TBL] [Abstract][Full Text] [Related]
20. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
Campbell C; Jacob P
BMC Neurol; 2003 Sep; 3():7. PubMed ID: 12962544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
